(News Bulletin 247) – Bristol Myers Squibb has announced top results from the phase 3 COMMANDS study, an open-label, randomized trial evaluating Reblozyl against the erythropoiesis-stimulating agent (ESA) epoetin alfa.

A trial conducted for the treatment of anemia in adult patients with very low, low or intermediate risk myelodysplastic syndromes (MDS) who required red blood cell (RBC) transfusions and had never received ESA.

The results show that almost twice as many patients treated with Reblozyl achieved superior transfusion independence with a concurrent increase in hemoglobin compared to epoetin alfa, including in clinically relevant subgroups.

Reblozyl demonstrated a durable response, with a median transfusion independence of nearly 2.5 years, ‘1 year longer than epoetin alfa’, the company says.

Additional results, which will be presented at the plenary session of the European Hematology Association Congress, will show that Reblozyl demonstrated clinical benefit in patients with a spectrum of MDS mutations.

Copyright (c) 2023 News Bulletin 247. All rights reserved.